Log in to save to my catalogue

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cance...

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cance...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8b39ff553a7a47e7a5a926087847574b

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

About this item

Full title

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Publisher

London: Nature Publishing Group UK

Journal title

Communications biology, 2021-10, Vol.4 (1), p.1235-1235, Article 1235

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of HDA...

Alternative Titles

Full title

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8b39ff553a7a47e7a5a926087847574b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8b39ff553a7a47e7a5a926087847574b

Other Identifiers

ISSN

2399-3642

E-ISSN

2399-3642

DOI

10.1038/s42003-021-02741-7

How to access this item